Asia
A new study published online has provided some hope for the citizens in India, with researchers suggesting that the Covaxin vaccine, developed by Bharat Biotech and Pennsylvania-based Ocugen, could neutralize the SARS-CoV-2 variant leading the second wave in the country.
Leaked documents from provincial and municipal governments in China reveal a slew of previously unreported severe adverse events related to COVID-19 vaccines made and administered in China.
It was a busy week for non-COVID-19-related clinical trial news, while fairly quiet on the COVID-19 arena. Here’s a look.
Ocugen’s plan to bring a COVID-19 vaccine developed by India-based Bharat Biotech later this year remains on track following an interim analysis of Phase III data that shows the vaccine demonstrated a 78% efficacy against mild to moderate infection and 100% efficacy against severe COVID-19.
Johnson & Johnson, Endo International, AbbVie’s Allergan unit and Teva Pharmaceutical will head to court this morning in California over claims the companies engaged in deceptive marketing practices that fueled the opioid crisis in America.
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.
This is by far the most exciting time in our history as Jubilant Biosys, and certainly the most exciting message Biosys has ever announced simply because of the sheer scale of transformation that we’ve taken on. It’s massive, very achievable, and ultimately truly transformative for us as colleagues, professionals, as an organization, and to our customers.
The main concern remains the KN95 mask’s regulation and lack of standardization. Also, to know if you can reuse KN95 mask or not, follow this article.
Under the terms of the deal, SciNeuro is paying Lilly cash upfront as well as various milestone payments and royalties. No financial details were disclosed.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
PRESS RELEASES